Materias dentro de su búsqueda.
Mostrando 4,741 - 4,760 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.37s Limitar resultados
  1. 4741
    por Watanabe, Junichiro
    Publicado 2015
    “…Women with estrogen receptor (ER)-positive human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2−) MBC, including unresectable locally advanced breast cancer, treated at a single institution were included in this study. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review
  2. 4742
    “…The objective of this study is to examine breast cancer patients’ preferences and willingness-to-pay (WTP) for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Patients’ preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments
  3. 4743
    “…Particularly, in breast cancer, anti-Her2/EGFR molecules represent the standard therapy for Her2-positive malignancies. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance
  4. 4744
    “…Serum sHER2 concentrations were measured by immunoassay in 244 primary NSCLC cases and 218 healthy controls. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma
  5. 4745
    “…The cell growth of HER2-overexpressing SKBR3 cell line was inhibited by VPA to a much greater degree than other cell lines studied. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation
  6. 4746
    “…A previous investigation indicated that ATA is more effective in inhibiting the growth of breast cancer especially cells with HER2 overexpression. However, the molecular mechanism(s) mediating this cytotoxic effect on HER2-positive breast cancer remained undefined. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways
  7. 4747
    “…Human epidermal growth factor receptor 2 (HER2) is a member of the HER family of proteins containing four receptor tyrosine kinases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER2 oncogene alterations
  8. 4748
    “…Here, we examined the effects of human epidermal growth factor-2 (HER2)-targeted PIT in combination with 5-fluorouracil (5-FU) compared to PIT alone for HER2-expressing human gastric cancer cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms
  9. 4749
    “…Trastuzumab is a remarkably effective therapy for patients with human epidermal growth factor receptor 2 (HER2) - positive breast cancer (BC). However, not all women with high levels of HER2 benefit from trastuzumab. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial
  10. 4750
    “…Patients with HER2-negative MBC received intravenous eribulin (1.4 mg/m(2) on days 1 and 8 of each 21-day cycle). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
  11. 4751
    por Howat, William J, Blows, Fiona M, Provenzano, Elena, Brook, Mark N, Morris, Lorna, Gazinska, Patrycja, Johnson, Nicola, McDuffus, Leigh‐Anne, Miller, Jodi, Sawyer, Elinor J, Pinder, Sarah, van Deurzen, Carolien H M, Jones, Louise, Sironen, Reijo, Visscher, Daniel, Caldas, Carlos, Daley, Frances, Coulson, Penny, Broeks, Annegien, Sanders, Joyce, Wesseling, Jelle, Nevanlinna, Heli, Fagerholm, Rainer, Blomqvist, Carl, Heikkilä, Päivi, Ali, H Raza, Dawson, Sarah‐Jane, Figueroa, Jonine, Lissowska, Jolanta, Brinton, Louise, Mannermaa, Arto, Kataja, Vesa, Kosma, Veli‐Matti, Cox, Angela, Brock, Ian W, Cross, Simon S, Reed, Malcolm W, Couch, Fergus J, Olson, Janet E, Devillee, Peter, Mesker, Wilma E, Seyaneve, Caroline M, Hollestelle, Antoinette, Benitez, Javier, Perez, Jose Ignacio Arias, Menéndez, Primitiva, Bolla, Manjeet K, Easton, Douglas F, Schmidt, Marjanka K, Pharoah, Paul D, Sherman, Mark E, García‐Closas, Montserrat
    Publicado 2014
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium
  12. 4752
    “…Our study was to identify the relationship between imaging features on ultrasound (US) and the recurrence score (RS) on a 21-gene expression assay in patients with oestrogen receptor (ER)-positive, HER2-negative breast cancer. 267 patients with ER-positive, HER-negative invasive breast cancer who underwent examinations using US and Oncotype DX assay were included. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer
  13. 4753
    “…In the neo-adjuvant setting, detection of TILs on biopsy before primary systemic therapy was associated with the ratio of patients achieving pathological complete response among 48 TNBCs (p = 0.024), but not among 58 HER2+ BCs (p = 0.30). The presence of TILs in surgical specimens after systemic therapy had prognostic value in HER2+ BC (RFS: p = 0.007). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
  14. 4754
    “…Of particular interest is the independent value of serum HER2 ECD levels, regardless of the tumor HER2 status, possibly linked to metastatic tumor heterogeneity.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients
  15. 4755
    “…Therefore, c-Met overexpression, HER-2 gene amplification, and SPTBN1-ALK gene fusion can coexist in lung adenocarcinoma and may become a potential biomarker of cancer refractory to crizotinib, chemotherapy, and radiotherapy as well as of a relatively poor prognosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy
  16. 4756
    “…Approximately 20% of HER2 positive breast cancer develops disease recurrence after adjuvant trastuzumab treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
  17. 4757
    “…Here, we tested localized therapy of DCIS in mice using the immunoconjugate (225)Ac linked-trastuzumab delivered through the intraductal (i.duc) route. Trastuzumab targets HER-2/neu, while the alpha-emitter (225)Ac (half-life, 10 days) delivers highly cytotoxic, focused doses of radiation to tumors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer
  18. 4758
    Publicado 1843
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Report of the Commissioners for Inquiring into Naval and Military Promotion and Retirement: With Appendices. Medical Department of the Army. Presented to Both Houses of Parliament by Command of Her Majesty. 1840
  19. 4759
    “…Finally, we show that IRS4 and ERBB2/HER2 synergistically induce tumorigenesis and that IRS4-expression confers resistance to HER2-targeted therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation
  20. 4760
    por Lee, Yu-Hsiang, Lai, Yun-Han
    Publicado 2016
    “…The target specificity of HIPPNPs to HER2-positive cells was demonstrated based on a 6-fold (P < 0.05) enhancement of uptake efficiency of HIPPNPs in MDA-MB-453/HER2(+) cells within 4 h as compared with that in MCF7/HER2(-) cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Synthesis, Characterization, and Biological Evaluation of Anti-HER2 Indocyanine Green-Encapsulated PEG-Coated PLGA Nanoparticles for Targeted Phototherapy of Breast Cancer Cells
Herramientas de búsqueda: RSS